DDInter1840 DDInter1627
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rufinamide
Trabectedin {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rufinamide (Compound)
Trabectedin (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)